Together with the observations in the mouse xenograft model, our results suggest that LPIN1 targeting is a good strategy for treating gefitinib-resistant NSCLC, which coincidently modulates survival factors, including PKC-NF-kB pathway signaling and altered lipid metabolism, such as LD formation. This evidence concerns the gene LPIN1 and non-small cell lung carcinoma.